Navigation Links
PDL BioPharma Announces First Quarter 2012 Financial Results
Date:5/3/2012

INCLINE VILLAGE, Nev., May 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Royalty revenues for the first quarter of 2012 increased five percent over the same period of 2011. Total revenues for the first quarter of 2012 were $77.3 million, compared to $83.3 million for the same period of 2011. Total revenue for the first quarter of 2011 included a one-time settlement payment of $10 million from UCB Pharma.

Royalty revenues for the first quarter of 2012 are based on fourth quarter 2011 product sales by PDL's licensees. The growth in royalty revenues was driven primarily by increased royalties from fourth quarter 2011 sales of Herceptin®, which is marketed by Genentech and Roche, Lucentis® and Xolair®, which are marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec.  Royalty revenue for the first quarter is net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

General and administrative expenses for the first quarter of 2012 were $6.9 million, compared with $5.8 million in the same period of 2011. The increase in expenses is mainly due to expenses incurred with the tender offer and exchange transactions for the 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes) and our efforts to acquire new royalty assets.

Net income for the first quarter of 2012 was $40.2 million, or $0.29 per diluted share as compared with net income of $44.5 million, or $0.25 per diluted share in the comparable quarter of 2011. Adjusting for the non-cash interest expense associated with our Series 2012 Notes and 3.75%
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
2. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
3. Laureate Biopharma Names James D. Utterback to Board of Directors
4. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
5. PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
6. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
7. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
8. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North American ... is the proud recipient of two Cisco® Partner Summit Country ... of the Year and Security Partner of the Year for ... taking place this week in Montreal . ... but two Cisco partner awards at this year,s conference," said ...
(Date:5/1/2015)... Investor-Edge has initiated coverage ... GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ), ... research report on Genetic Technologies can be accessed ... 2015, the NASDAQ Composite ended at 4,941.42, down ...
(Date:5/1/2015)... DALLAS , May 1, 2015 ... report "Antibody Production Market by Product (Equipment, Consumables), by ... (Biopharmaceutical Companies, Diagnostic Labs, Research Institutes) - Analysis ... the report studies the global Antibody Production Market ... This market is expected to reach $2.572 Billion ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... The New Jersey Board of,Pharmacy has ... pharmacy,technicians at Wedgewood Pharmacy. The program was ... Affairs Department. Upon,completion of the program, each ... high level of competence in all state ...
... ORLANDO, Fla., Sept. 7 Daniel B. Yarosh, ... keynote presentation at the 11th,Annual Sunscreen Symposium today ... 6th-9th) of cosmetic chemists is sponsored by the,Florida ... Yarosh will,present "Beyond Sunscreens: DNA Repair and Photoaging" ...
... Genmab Announces ofatumumab Appeared More Effective Than rituximab ... ... Genmab A/S,(OMX: GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared ... mechanism, than rituximab in a pre-clinical study. The CD20,antibodies were ...
Cached Biology Technology:NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program 2NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program 3AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium 2Genmab Announces Encouraging Preclinical Data for ofatumumab 2
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Medicine researchers have discovered how new neurons born from ... the brain where they can replace old and dying ... can be specifically targeted to brain regions affected by ... Zhou and graduate student Kwan L. Ng in the ...
... last year at Petrified Forest National Park in Arizona throws ... arose more than 210 million years ago at the end ... creatures from the Late Triassic known only from their teeth, ... dinosaurs like Stegosaurus and Triceratops, which roamed the world millions ...
... science gets wiser, so do the bugs. The rates ... in the hospital have been increasing steadily in recent ... 15 issue of Clinical Infectious Diseases, now available online. ... due in part to inappropriate prescribing and overuse of ...
Cached Biology News:Researchers discover stem cell 'guide' that may be key for targeting neural stem cell treatments 2Agilent Technologies introduces high-capacity human protein removal system for proteomics research 2Agilent Technologies introduces high-capacity human protein removal system for proteomics research 3Agilent Technologies introduces high-capacity human protein removal system for proteomics research 4Two studies document rise of superbugs in the environment 2Two studies document rise of superbugs in the environment 3
Mouse Anti-Gemin2...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
... for cryogenic vials. Racks ... stainless steel boxes for 2ml, ... Vapor phase or Liquid ... risers to be ordered separately ...
... J. Karn (1995) This ... information and methods for the study of ... cycle; reverse transcriptase, ribonuclease H, integrase and ... RNA binding assays; Tat and Rev assays; ...
Biology Products: